Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma

Disni Muringampurath-John, Christopher R. Flowers, Michael Toscano, Chen Zhengjia, Jonathan L. Kaufman, Martha Arellano, Leon Bernal-Mizrachi, Leonard T. Heffner, Mary Jo Lechowicz, Morgan McLemore, Elliott Winton, David L. Jaye, Sagar Lonial, Hanna Jean Khoury

Research output: Contribution to journalLetter

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)725-727
Number of pages3
JournalLeukemia and Lymphoma
Volume53
Issue number4
DOIs
StatePublished - Apr 1 2012

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Muringampurath-John, D., Flowers, C. R., Toscano, M., Zhengjia, C., Kaufman, J. L., Arellano, M., Bernal-Mizrachi, L., Heffner, L. T., Lechowicz, M. J., McLemore, M., Winton, E., Jaye, D. L., Lonial, S., & Khoury, H. J. (2012). Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 53(4), 725-727. https://doi.org/10.3109/10428194.2011.619019